Piper Sandler analyst Pearce Hammond maintains Itron (NASDAQ:ITRI) with a Neutral and lowers the price target from $51 to $50.
Zhongchao Announces Naiditawei Enrolled As A Listed Online Procurement Drug In Ten Provinces In China
Zhongchao Inc. (NASDAQ:ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced